NCT05967156

Brief Summary

Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for not_applicable heart-failure

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 15, 2023

Completed
17 days until next milestone

First Posted

Study publicly available on registry

August 1, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 3, 2025

Completed
Last Updated

June 6, 2025

Status Verified

June 1, 2025

Enrollment Period

2 years

First QC Date

July 15, 2023

Last Update Submit

June 5, 2025

Conditions

Heart FailureHemodialysis

Outcome Measures

Primary Outcomes (1)

  • Brain Natriuretic Peptide

    serum level

    one month after administration

Study Arms (1)

Empagliflozin

EXPERIMENTAL

Heart failure dialysis patients will be treated with Empagliflozin

Drug: Empagliflozin10Mg Tab

Interventions

Empagliflozin10Mg TabDRUG

10 mg daily

Also known as: Abide
Empagliflozin

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Heart failure on dialysis with residual renal function

You may not qualify if:

  • Dialysis patients with no residual urine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nooshin Dalili

Tehran, 1666663421, Iran

Location

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Dalili

    SMBU

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 15, 2023

First Posted

August 1, 2023

Study Start

June 1, 2023

Primary Completion

June 1, 2025

Study Completion

June 3, 2025

Last Updated

June 6, 2025

Record last verified: 2025-06

Locations

IR(1)